Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
886,6 DKK | +2,28% | +2,77% | +27,00% |
25/04 | NOVO NORDISK : JP Morgan herhaalt koopadvies | ZD |
25/04 | Scholz belooft steun voor farmaceutische sector in Duitsland nu Merck investeert | RE |
Vakgebied
- producten voor de behandeling van diabetes en obesitas (92,6%);
- producten voor de behandeling van zeldzame ziekten (7,4%): bedoeld voor de behandeling van hemofilie, bloedziekten, hormonale stoornissen, enz.
De netto-omzet is geografisch als volgt verdeeld: Europa/Midden-Oosten/Afrika (21,9%), de Verenigde Staten (54,9%), Noord-Amerika (3,9%), China (7,2%) en overige (12,1%).
Aantal werknemers: 63 845
Verkoop per activiteit
DKK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Diabetes and Obesity Care
92,6
%
| 156 412 | 88,4 % | 215 098 | 92,6 % | +37,52% |
Rare Disease
7,4
%
| 20 542 | 11,6 % | 17 163 | 7,4 % | -16,45% |
Verkoop per regio
DKK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
54,9
%
| 84 656 | 47,8 % | 127 534 | 54,9 % | +50,65% |
EMEA
21,9
%
| 44 236 | 25,0 % | 50 867 | 21,9 % | +14,99% |
Rest of the World
12,1
%
| 25 402 | 14,4 % | 28 078 | 12,1 % | +10,53% |
China
7,2
%
| 16 209 | 9,2 % | 16 687 | 7,2 % | +2,95% |
Canada
3,9
%
| 6 451 | 3,6 % | 9 095 | 3,9 % | +40,99% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 01-01-91 | |
Director of Finance/CFO | 53 | 01-01-99 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01-10-15 |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 57 | 01-01-18 |
Chief Operating Officer | 54 | 01-01-92 | |
Chief Tech/Sci/R&D Officer | 54 | 01-01-99 | |
Daniel Bohsen
IRC | Investor Relations Contact | - | 01-03-20 |
Tania Sabroe
HRO | Human Resources Officer | 47 | 01-01-07 |
General Counsel | - | - | |
Sergey Manelis
PRN | Corporate Officer/Principal | - | 13-07-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19-03-15 |
Helge Lund
CHM | Chairman | 61 | 23-03-17 |
Martin MacKay
BRD | Director/Board Member | 68 | 01-03-18 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23-03-17 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01-03-18 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25-03-21 |
Director/Board Member | 58 | 01-01-92 | |
Christina Law
BRD | Director/Board Member | 57 | 01-01-22 |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22-03-18 |
Director/Board Member | 59 | 24-03-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 10 | 1 075 000 000 | 0 | 0 | 70,47 % |
Aandeel B | 1 | 3 435 000 000 | 3 178 045 788 ( 92,52 %) | 51 700 000 ( 1,505 %) |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
NOVO NORDISK A/S 1.42% | 48 674 207 | 1.42% | 6 223 028 030 $ |
NNIT A/S 17.50% | 4 375 000 | 17.50% | 68 672 756 $ |
INNATE PHARMA 12.14% | 9 817 546 | 12.14% | 23 167 445 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
NNE A/S
NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The private company is based in Soborg, Denmark. |
Engineering & Construction
|
Novo Nordisk Region Europe A/S
Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. |
Financial Conglomerates
|
Novo Nordisk Health Care AG
Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Novo Nordisk India Pvt Ltd.
Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The private company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Finance (Netherlands) BV
|
Finance/Rental/Leasing
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+27,00% | 556 mld. | |
+25,83% | 653 mld. | |
-6,76% | 354 mld. | |
+20,34% | 331 mld. | |
+3,00% | 296 mld. | |
+13,09% | 233 mld. | |
+5,46% | 201 mld. | |
-9,61% | 193 mld. | |
-6,26% | 144 mld. | |
-11,77% | 143 mld. |
- Beurs
- Aandelen
- Koers NOVO B
- Onderneming Novo Nordisk A/S